Binocs’ Post

On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. https://lnkd.in/gVupQ2Wr

Brian and Atalah have an incredible ability to go from macroscopic to microscopic in a matter of minutes to really hone in on your needs while remaining cognoscente of the big picture. Let me know if you're starting your clinical journey, taking your first step into expanded access or just want to meet a few likeminded industry professionals - happy to provide an introduction! #expandedaccess, #compassionateuse, #clinicaltrials, #oncology, #hematology, #hematologyoncology

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #OrthopedicOncology #CancerTreatment #GlobalHealthcare #MedicalAdvancements #PatientCare #Chemotherapy #Surgery #Hospitals #Clinics #PharmaceuticalIndustry

Symbio presents a white paper on Psoriasis on #worldpsoriasisday

Sandoz has received marketing authorization from the European Commission for Pyzchiva® (biosimilar ustekinumab), developed by Samsung Bioepis. Pyzchiva® is approved for use in treating chronic inflammatory diseases within gastroenterology, dermatology, and rheumatology. This approval marks a significant advancement in Sandoz's growth strategy, offering European patients an additional treatment option. The regulatory submission included extensive data from analytical, preclinical, and clinical studies. Sandoz entered a development and commercialization agreement with Samsung Bioepis in 2023, granting Sandoz commercialization rights in various regions while Samsung Bioepis retains responsibilities for development, registration, and manufacturing. Pyzchiva® matches the reference medicine, a monoclonal antibody targeting interleukin (IL)-12/23, for treating autoimmune disorders. #marketintelligence #competitiveintelligence #marketsmind #pharmaceutical #sandoz #ustekinumab

On December 28, 2023, I had the opportunity to attend the Sheryan Conference on Hematology. The conference provided valuable insights into the latest advancements and research in the field of hematology. It was an enriching experience that deepened my understanding of blood disorders and their treatments. #Hematology #SheryanConference #MedicalResearch #ContinuousLearning #Pharmacy

#Haemophilia is an inherited disorder. In #patients with haemophilia, #blood does not clot normally. For diagnosis of haemophilia, #doctors generally do blood tests to see if your blood clots at a normal rate and to check if you have enough #clottingfactors which are proteins that help make your blood to clot. #clinicaltrial #medicalaffairs #research& development

Have you listened to the latest Mend The Gap epsiode yet? 🎙 In this episode, Laura Enyedi, MD, and Susan MacDonald, MD, discuss leadership in ophthalmology with Adrienne Graves, as well as her career in pharmaceuticals. Listen here:

Big news in ophthalmology. Tenpoint Therapeutics, Ltd., a Sofinnova Partners portfolio company, has joined forces with Visus Therapeutics to build the next generation of ophthalmic therapies to rejuvenate the aging eye. Together, they’re building a robust pipeline of innovative therapies, starting with BRIMOCHOL™ PF, a presbyopia-correcting eye drop set for NDA filing in 2025 and a U.S. launch in 2026. As part of the strategic move, Henric Bjarke has been appointed CEO. He brings extensive leadership experience from Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia. Learn more about how Tenpoint is shaping the future of ophthalmic medicines via the link in the comments.

With a big difference between the first and 10th position holder i.e., ~$9B (Between Eylea and Medrol sales). We at Octavus Consulting present to you Top10 Ophthalmology 👀 drugs based on 2023 revenue 💸 Some Key 🗝 Insights 💡: 💠Eylea by Regeneron & Bayer secured the 🥇 first spot by earning $9.38B and it was first approved in 2011 (These revenues include Eylea & Eylea HD). Interestingly, Eylea has competition from 3 approved biosimilars by Biocon, Samsung Bioepis/ Biogen & Formycon AG 💠Roche’s Vabysmo which was approved in 2022 is at 🥈 2nd spot by $2.8B. It is interesting to note that the difference in first and 2nd spot revenue is close to $6.5B approx. 💠For the 🥉 3rd place we have Roche and Novartis’ Lucentis with $2.02B of sales. Again, it is surprising to see such high sales after 5 approved biosimilars in US & EU from Coherus BioSciences, Samsung Bioepis, Midas Pharma, & STADA Group Now some interesting facts which are not covered in these 10 slides 1.      AbbVie’s Humira could also have been considered in Opthalmology and would have been the top drug with $14.4B sales because it is approved in Uveitis. But because we had limited information on the ophthalmic share in the revenue, we left it out. Even Adalimumab’s Amgen biosimilar has been approved in Uveitis and has overall revenue of $626M 2.      Similar to Humira, Mallinckrodt Pharmaceuticals’s Acthar Gel which is again approved across multiple Immunology indication is also approved in few ophthalmic ones such as keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation. Couldn’t have been included even with $425M overall sales because lack of transparency in the ophthalmic share So, if you found our analysis interesting. Please do follow Octavus consulting and reach us if your looking to explore CI deep dive in Ophthalmology or more reach us at bd@octavusconsulting.com #competitiveanalysis #competitiveintelligence #Ophthalmology #eyedisorder #eylea #research #insights